39 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28105277	33	Design and Synthesis of Novel Meta-Linked Phenylglycine Macrocyclic FVIIa Inhibitors.	Bristol-Myers Squibb
27914800	11	Discovery of a new isomannide-based peptidomimetic synthetized by Ugi multicomponent reaction as human tissue kallikrein 1 inhibitor.	Universidade Federal Fluminense
27994741	48	Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors.	Bristol-Myers Squibb R & D
27612545	37	Synthesis and P1' SAR exploration of potent macrocyclic tissue factor-factor VIIa inhibitors.	Bristol-Myers Squibb Research & Development
27455395	66	Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa-Tissue Factor Complex.	Bristol-Myers Squibb R & D
27015008	51	Atropisomer Control in Macrocyclic Factor VIIa Inhibitors.	Bristol-Myers Squibb Research & Development
26848109	8	The natural flavone fukugetin as a mixed-type inhibitor for human tissue kallikreins.	Campus
26704266	80	Novel phenylalanine derived diamides as Factor XIa inhibitors.	Bristol-Myers Squibb
26151189	56	Structure-Based Design of Macrocyclic Coagulation Factor VIIa Inhibitors.	TBA
26005539	23	Discovery of a Potent Parenterally Administered Factor XIa Inhibitor with Hydroxyquinolin-2(1H)-one as the P2' Moiety.	Bristol-Myers Squibb
25728130	79	Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties.	Bristol-Myers Squibb
24224573	31	Optimization of O3-acyl kojic acid derivatives as potent and selective human neutrophil elastase inhibitors.	Universidade De Lisboa
23294255	114	Development of new cyclic plasmin inhibitors with excellent potency and selectivity.	Philipps University Marburg
22607152	7	Kallikrein protease activated receptor (PAR) axis: an attractive target for drug development.	Universit£
22386244	4	Human kallikrein 6 inhibitors with a para-amidobenzylanmine P1 group identified through virtual screening.	Sanofi Pharmaceuticals
10669559	180	Protease inhibitors: current status and future prospects.	University Of Queensland
9301673	234	Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine.	Klinikum Der Friedrich-Schiller-Universit£T Jena
1527787	11	Synthesis and biological activity of ketomethylene pseudopeptide analogues as thrombin inhibitors.	Thrombosis Research Institute
10915051	43	The design and synthesis of thrombin inhibitors: analogues of MD805 containing non-polar surrogates for arginine at the P1 position.	Novartis Horsham Research Centre
10091673	21	Synthesis of potent and selective inhibitors of human plasma kallikrein.	The Procter & Gamble
22047802	8	The arginine mimickingß-amino acidß³hPhe(3-H2N-CH2) as S1 ligand in cyclotheonamide-basedß-tryptase inhibitors.	Universit£T Bielefeld
	78	Synthesis and evaluation of 2-aryl-4H-3,1-benzoxazin-4-ones as C1r serine protease inhibitors	TBA
15801822	28	9-hydroxyazafluorenes and their use in thrombin inhibitors.	Merck Research Laboratories
15582418	103	Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties.	Abbott Laboratories
15149645	92	Interaction with the S1 beta-pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine urokinase inhibitors.	Abbott Laboratories
15080981	72	N,N-Dialkylated 4-(4-arylsulfonylpiperazine-1-carbonyl)-benzamidines and 4-((4-arylsulfonyl)-2-oxo-piperazin-1-ylmethyl)-benzamidines as potent factor Xa inhibitors.	Millennium Pharmaceuticals
15013006	69	Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifs.	Millennium Pharmaceuticals
14980671	78	1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 3: Design, synthesis and SAR of orally bioavailable benzamidine-P4 inhibitors.	Millennium Pharmaceuticals
14980670	107	1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 2: A survey of P4 motifs.	Millennium Pharmaceuticals
12039584	59	Design, synthesis, and SAR of monobenzamidines and aminoisoquinolines as factor Xa inhibitors.	Millennium Pharmaceuticals
12039583	140	Design, synthesis and biological activity of novel non-amidine factor Xa inhibitors. Part 1: P(1) structure-activity relationships of the substituted 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides.	Millennium Pharmaceuticals
10425106	12	4-Heterocyclohexanone-based inhibitors of the serine protease plasmin.	Brown University
9873535	13	Highly efficient and versatile synthesis of libraries of constrained beta-strand mimetics.	Molecumetics
7739010	118	Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin.	Thrombosis Research Institute
7629790	32	New orally active serine protease inhibitors.	Minase Research Institute
2136920	39	New leupeptin analogues: synthesis and inhibition data.	University Of Arkansas
24058293	12	Modulation of global low-frequency motions underlies allosteric regulation: demonstration in CRP/FNR family transcription factors.	Durham University
11784141	11	Beta-strand mimicking macrocyclic amino acids: templates for protease inhibitors with antiviral activity.	University Of Queensland